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To investigate the importance of the vascular basal
lamina in tumor blood vessel morphogenesis and
function, we compared vessel development, vessel
function, and progression of B16F10 melanoma tu-
mors in the brains of wild-type and collagen VI-null
mice. In 7-day tumors in the absence of collagen VI,
the width of the vascular basal lamina was reduced
twofold. Although the ablation of collagen VI did not
alter the abundance of blood vessels, a detailed analysis
of the number of either pericytes or endothelial cells (or
pericyte coverage of endothelial cells) showed that col-
lagen VI-dependent defects during the assembly of the
basal lamina have negative effects on both pericyte mat-
uration and the sprouting and survival of endothelial
cells. As a result of these deficits, vessel patency was
reduced by 25%, and vessel leakiness was increased
threefold, resulting in a 10-fold increase in tumor hyp-
oxia along with a fourfold increase in hypoxia-induc-
ible factor-1 expression. In 12-day collagen VI-null tu-
mors, vascular endothelial growth factor expression
was increased throughout the tumor stroma, in contrast
to the predominantly vascular pattern of vascular endo-
thelial growth factor expression in wild-type tumors.
Vessel size was correspondingly reduced in 12-day col-
lagen VI-null tumors. Overall, these vascular deficits
produced a twofold decrease in tumor volume in colla-
gen VI-nullmice, confirming that collagen VI-dependent
basal lamina assembly is a critical aspect of vessel
development. (Am J Pathol 2012, 180:1145–1158; DOI:
10.1016/j.ajpath.2011.11.006)
Microvessels are composed primarily of three elements:
endothelial cells, pericytes, and vascular basal lamina(basement membrane).1 These components are not in-
dependent entities but interact in complex ways to deter-
mine vessel development, maintenance, and function.2–4
We have been interested in determining the respective
contributions of these three components to vascular bi-
ology, especially as they relate to pathologic microves-
sels, including those in tumors. We previously reported
that genetic ablation of the NG2 proteoglycan, a cell
surface component of microvascular pericytes, results in
greatly reduced growth of B16F10 melanoma tumors in
mouse brain.5 We were able to attribute at least part of
this reduced tumor growth to deficits in the tumor vascu-
lature caused by the absence of NG2 from microvascular
pericytes. Compared with NG2-positive pericytes in wild-
type hosts, NG2-negative pericytes in NG2-null hosts
exhibited a greatly diminished ability to interact with and
ensheath endothelial cells in the vasculature of the
B16F10 tumors. This loss of NG2-dependent pericyte/
endothelial cell cross talk, known to be mediated by
NG2/1 integrin interaction,6 led to deficits in pericyte
and endothelial cell maturation. This was manifested
most dramatically by a large decrease in assembly of the
vascular basement membrane. As a result of these
changes at the molecular and cellular levels, the function
of tumor vessels was impaired in the NG2-null mouse.
Vessel patency was reduced and vessel leakiness was
increased, leading to a large increase in tumor hypoxia.
Because of the link between reduced pericyte/endo-
thelial cell interaction and reduced basal lamina assem-
bly in the NG2-null mouse, we were not able to evaluate
the respective contributions of these two processes dur-
ing tumor vessel development. To pursue the dissection
of these phenomena, we have investigated the collagen
VI-null mouse7 as a model in which it might be possible to
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in the absence of major changes in pericyte/endothe-
lial cell dynamics. Collagen VI is a rather unique col-
lagen species that provides a link between cell surface
receptors, including NG28 and integrins,9 and other
collagens such as collagens I and IV that are involved
in basal lamina assembly.10,11 Our previous study that
deposition of the collagen IV-containing vascular basal
lamina in B16F10 tumor vessels was greatly diminished
by the ablation of collagen VI5 suggested the possible
utility of the collagen VI-null mouse for examining the
effects of basal lamina deficits on vessel development
and function.
For analyzing vessel development and function, we
have assembled a number of tools that allow us to eval-
uate changes in pericytes and endothelial cells, deposi-
tion of the basal lamina, levels of vessel patency and
leakiness, and the extent of tumor hypoxia.5 In this report
we have used these tools in the context of B16F10 mel-
anoma allografts growing in wild-type versus collagen
VI-null mouse brains. In addition to providing a milieu for
vessel development, the B16F10 tumors also provide an
additional means of assessing vessel functionality. Be-
cause tumor progression exhibits an absolute require-
ment for tumor vascularization,12,13 tumor growth serves
as an overall readout of vessel development and perfor-
mance. In the end, because of the intimate relation
among pericytes, endothelial cells, and the basal lamina,
we were only partially successful in dissecting the effects
of deficits in basal lamina assembly from the effects of
deficits in pericyte/endothelial cell dynamics. Our results
nevertheless show for the first time that collagen VI-de-
pendent assembly of the vascular basement membrane
is a critical factor in determining vessel functionality and
thus in determining tumor progression.
Materials and Methods
Cell Lines
B16F10 mouse melanoma cells (American Type Culture
Collection, Manassas, VA) were maintained in Dulbec-
co’s modified Eagle’s medium containing 10% fetal calf
serum, 2 mmol/L glutamine, 100 IU/mL penicillin, and 100
mg/mL streptomycin sulfate.14 These cells do not ex-
press the NG2 proteoglycan.
Animals
Wild-type C57Bl/6 mice and collagen VI-null C57Bl/6
mice7 were maintained in the Sanford-Burnham Vivarium
(fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care). All animal pro-
cedures were performed in accordance with Office of
Laboratory Animal Welfare regulations and were ap-
proved by Sanford-Burnham Institutional Animal Care
and Use Committee review before execution.Intracranial Microinjection and Growth of Tumors
B16F10 cells were harvested and re-suspended in Dul-
becco’s modified Eagle’s medium at a density of 5  106
cells/mL. From this suspension, 2 L (104 cells) were
microinjected into the forcep minor of the corpus callo-
sum (stereotactic coordinates relative to bregma: 2 mm
lateral, 1 mm rostral, 2 mm deep) of wild-type and type VI
collagen-null mice (13 to 15 weeks old) under Avertin
anesthesia.5 An injection rate of 0.2 L/min was main-
tained with the use of a Stoelting micropump connected
to a 10-L Hamilton syringe with a 26-gauge needle.
Animals were monitored daily for signs of distress, such
as weight loss, seizures, posturing, and nasal and/or
periorbital hemorrhage. However, these symptoms were
never observed during our study. In general, cohorts of
from four to seven mice, each bearing a single tumor,
were used in each of the studies described below. At 7,
12, and 15 days after injection of B16F10 cells, animals
under Avertin anesthesia were perfused with 1% parafor-
maldehyde, and the brains were removed for analysis.
Exceptions to this euthanasia regimen were cases in
which mice were injected with FITC-dextran, FITC-Lyco-
persicon esculentum agglutinin (LEA) lectin, pimonida-
zole, or PI as described below.
Measurement of Tumor Volume
After measuring the long and short axes of the tumors,
brains were sliced through the midline of the tumor to
allow measurement of tumor depth.5 Tumor volumes at
days 7, 12, and 15 were calculated with the following
formula: V  0.52  A  B  C, where A is the length of
the short axis, B that of the long axis, and C that of tumor
depth. These measurements were greatly facilitated by
the pigmentation of the B16F10 melanoma cells. At each
time point, at least seven tumors were examined for each
genotype.
Immunohistochemistry and Microscopy
Fixed brains were cryoprotected by overnight immersion
in 20% sucrose and then frozen in OCT compound.
These blocks were used to prepare 20-m sections on a
Reichert-Jung 1800 cryostat microtome. Endothelial
cells, pericytes, vascular basal lamina, and apoptotic
cells were identified by staining with combinations of two
or three antibodies.5,15 Endothelial cells in tumor vessels
were labeled with rat anti-CD31 (1:500; BD Pharmingen,
San Diego, CA), hamster anti-CD31 (1:500; Pierce Endo-
gen, Rockford, IL), or goat anti-VEGFR-3 (1:500; R&D
Systems, Minneapolis, MN). Pericytes were labeled with
rabbit anti-PDGFR- (1:1005) or rabbit anti-NG2 (1:1005),
and mature pericytes were stained with cyanine 3-conju-
gated mouse anti--SMA (1:500; Sigma-Aldrich, St.
Louis, MO). The vascular basal lamina was examined
with rabbit anti-collagen IV (1:500; Millipore, Billerica,
MA), rabbit anti-collagen I (1:500; Rockland Immuno-
chemicals, Inc., Gilbertsville, PA), or rabbit anti-laminin-
111 (1:500; a generous gift from Dr. Eva Engvall, Sanford-
Burnham Medical Research Institute, La Jolla, CA).
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activated caspase-3 (1:500; R&D Systems). Lymphatic
vessels were identified with rabbit anti-LYVE-1 (1:500;
AngioBio Co., Del Mar, CA). Hypoxia-inducible factor
(HIF)-1 was detected with a rabbit anti-HIF-1 antibody
provided by Dr. Gary Chiang Sanford-Burnham Medical
Research Institute, La Jolla, CA, USA. VEGF was de-
tected with goat antibody against mouse VEGF (1:50;
R&D Systems).15 Secondary antibodies included FITC-,
cyanine 3-, or cyanine 5-labeled (1:400; Jackson
ImmunoResearch Laboratories Inc., West Grove, PA) and
Alexa 488-, or Alexa 568-labeled (1:250; Invitrogen,
Carlsbad, CA) goat or donkey anti-rat, anti-hamster, anti-
rabbit, or anti-goat immunoglobulin G. Examination and
image capture (TIFF images) from immunostained sec-
tions were accomplished with a Fluoview 1000 (Olympus,
Tokyo, Japan) Laser Point Scanning Confocal Micro-
scope and an Inverted TE300 Nikon Fluorescence Micro-
scope (Nikon, Tokyo, Japan) as described previously.5
For confocal imaging, serial 1-m optical sections across
the entire 20-m thickness of the histologic specimens
were obtained from four to five tumors at each time point.
Areas (number of pixels) with immunostaining greater
than a set threshold were quantified with computer-
based morphometry software (Image-Pro Plus version
4.5; Media Cybernetics, Inc., Bethesda, MD).
Measurement of Vascular Basal Lamina
Thickness
Vascular basal lamina thickness was quantified by mea-
suring the distance between CD31-positive endothelial
cells and the outermost boundary of the basal lamina, as
defined by immunostaining for collagen IV, collagen I, or
laminin-111. This distance was measured with Image-Pro
Plus version 4.5 software (Media Cybernetics, Inc.). For
statistical analysis, 10 sites per vessel were randomly
selected, and five tumor vessels in each tumor were
sampled (four to five tumors for each genotype).
Measurement of Vascular Density
Tumor sections were immunolabeled for CD31, and num-
bers of tumor blood vessels were counted in fluores-
cence images acquired with an inverted TE300 Nikon
fluorescence microscope. Four randomly selected areas
were sampled in each of five tumors from wild-type mice
and five tumors from collagen VI-null mice. Average ves-
sel densities were then quantified as vessel number per
10,000 m2 of tumor area.
Quantification of Sprouting Endothelial Cells
Sprouting endothelial tip cells in tumor vessels were la-
beled with goat anti-VEGFR-3,16 whereas the bulk of non-
sprouting endothelial cells were labeled for CD31.
Sprouting endothelial cells positive for VEGFR-3 and neg-
ative for CD31 were counted in five tumor vessels in each
tumor (four to five tumors for each genotype). Sproutingendothelial cell abundance was expressed as the num-
ber of cells per unit of CD31-positive vessel area.
Determination of Vascular Leakage
FITC-dextran (250 kDa; Sigma-Aldrich) was injected in-
travenously (0.1 mL of a 50-mg/mL solution) via the tail
veins of wild-type and collagen VI-null mice under Avertin
anesthesia.5 After 10 minutes to allow circulation, mice
were cervically dislocated while still under anesthesia.
Whole brains with tumors were removed without perfu-
sion and fixed overnight in 1% paraformaldehyde. After
cryoprotection in 20% sucrose, material was frozen in
OCT compound. Cryosections (20 m) were prepared
and immunostained for CD31. The extent of FITC-dextran
leakage from blood vessels was estimated on the basis of
green fluorescence located external to CD31-positive
vascular structures. With the use of Image-Pro Plus ver-
sion 4.5 software (Media Cybernetics, Inc.), the borders
of CD31-labeled blood vessels were identified so that
extravascular FITC-dextran could be quantified by count-
ing green pixels external to red blood vessels. Vascular
leakage was defined as total extravascular FITC-dextran
per tumor field. At least five microscopic fields were ex-
amined in four to five tumors from each genotype.
Determination of Vascular Patency
Functional connection of tumor vessels to the circulation
was assessed in Avertin-anesthetized mice by tail vein
injection of 0.1 mL of 0.5 mg/mL FITC-labeled LEA lectin
(Vector Laboratories, Burlingame, CA).5,15,17 After circu-
lation for 3 minutes to allow binding to the vascular en-
dothelium, unbound lectin was cleared by perfusion with
saline, followed by perfusion with 1% paraformaldehyde
for tissue fixation. Labeling of vessels with FITC-LEA lec-
tin was compared with immunolabeling for CD31 as a
means of quantifying both the percentage of patent ves-
sels and the abundance of nonpatent vessels. At least
five microscopic fields were examined in four to five tu-
mors from each genotype.
Determination of Tumor Hypoxia
Tumor hypoxia was evaluated with a Hypoxyprobe-1 kit
(Hypoxyprobe, Inc., Burlington, MA). Tumor-bearing
mice were injected intravenously with 60 mg/kg pi-
monidazole hydrochloride and then perfused with 1%
paraformaldehyde after a 60-minute incubation pe-
riod.5,17 Brains were postfixed for 60 minutes in 1% para-
formaldehyde, followed by cryoprotection in 20% su-
crose. Brains were then frozen in OCT, and 20-m
sections were prepared. For visualization of hypoxic ar-
eas, sections were incubated overnight with FITC-conju-
gated mouse anti-pimonidazole hydrochloride (1:100;
Hypoxyprobe, Inc.) antibody. Levels of hypoxia were de-
termined by quantifying green pixels per tumor area. At
least five microscopic fields were examined in four to five
tumors from each genotype.
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Tumor cell necrosis was assessed in tumor-bearing,
Avertin-anesthetized mice after tail vein injection of PI (50
L, 2.5 mg/mL; Sigma-Aldrich).18 After a 5-hour incuba-
tion period, mice were also injected with pimonidazole
hydrochloride for parallel assessment of tumor hypoxia
(additional 60-minute incubation period).5,17 After perfu-
sion with 1% paraformaldehyde, brains were postfixed for
60 minutes in the same fixative, followed by cryoprotec-
tion in 20% sucrose. Brains were frozen in OCT, and
20-m sections were prepared. Hypoxia was assessed
as described above. PI-positive cells were identified by
fluorescence. For quantification of PI-positive cells, at
least five microscopic fields were examined in four to five
tumors for each genotype.
Statistical Analysis
All results were expressed as mean  SE. Statistical
analyses were performed with the two-tailed t-test. P 
0.05 was considered statistically significant. Two observ-
ers independently examined all histologic specimens.
Results reported here are from examinations made by
observer 1, who was not blinded as to mouse genotype.
However, all results were confirmed by observer 2, who
was blinded as to mouse genotype and whose quantifi-
cations were within 10% of the values obtained by ob-
server 1.
Results
Intracranial Melanoma Progression Is Retarded
in Collagen VI-Deficient Mice
To examine the effect of collagen VI deficiency on mela-
noma progression, NG2-negative B16F10 melanoma
cells were microinjected intracranially into the subcortical
white matter (corpus callosum) of both wild-type and
collagen VI-null mice. Melanoma sizes in the brain were
measured at 7, 12, and 15 days after injection. The av-
erage melanoma volume in collagen VI-null mice was half
that seen in wild-type mice at 12 and 15 days after injec-
tion (Figure 1A). At 7 days after injection, tumors were too
small to allow accurate macroscopic measurements of
volume so that differences between wild-type and colla-
gen VI-null mice were not significant. However, micro-
scopic examination of sections of 7-day tumors allowed
accurate measurements of cross-sectional tumor area,
showing a 20% decrease in collagen VI-null mice (Figure
1B). This would translate into a 30% decrease in tumor
volume in collagen VI-null mice. These results show that
the progression of intracranial melanoma growth is
slowed by the absence of collagen VI, with deficits in
tumor growth becoming evident as early as day 7 after
tumor initiation.Vascular Basal Lamina Deposition Is Reduced
by Collagen VI Ablation
We previously reported reduced vascular basal lamina
deposition associated with B16F10 tumor vessels in col-
lagen VI-null mice.5 We have now extended this analysis
in more depth with the use of 7-day tumors from wild-type
and collagen VI-null mice. This time point was chosen on
the basis of our previous finding that vascular deficits in
the NG2-null mouse were most apparent at the stage
when tumor size first began to diverge from that seen in
wild-type hosts.5 In the collagen VI-null mouse this diver-
gence begins to be evident at day 7 of tumor growth
(Figure 1, A and B). We immunolabeled vessels in 7-day
tumor sections for several extracellular matrix (ECM) pro-
teins, including collagen IV, collagen I, and laminin-111.
Collagen IV is the main collagen species present in vas-
cular basement membranes. We found that most tumor
blood vessels in wild-type mice were well covered by a
collagen IV-positive basal lamina (Figure 1, C and D). In
contrast, many segments of tumor vessels in collagen
VI-null mice were more poorly covered by the vascular
basal lamina (Figure 1, E and F). Quantification of this
phenomenon showed that, although 30% of vessel sur-
faces were not covered by collagen IV in tumors in wild-
type mice, this figure rose to 46% in tumors growing in
collagen VI-null mice (Figure 1G). Measurements of vas-
cular basal lamina width showed even more dramatic
differences between tumor vessels in wild-type and col-
lagen VI-null mice. The average thickness of the collagen
IV-positive vascular basal lamina was reduced by 45% in
collagen VI-null mice compared with that found in wild
type (Figure 1H). Similar reductions in basal lamina thick-
ness were seen with immunolabeling for collagen I and
laminin-111 (Figure 1, I and J), showing that reduced
vascular basal lamina assembly in the collagen VI-null
mouse is independent of the ECM marker used.
Vascular Cell Recruitment, Vascular Density,
and Pericyte Coverage of Endothelial Cells Are
Not Altered by Collagen VI Ablation
We previously reported that ablation of the NG2 pro-
teoglycan results in reduced pericyte coverage of endo-
thelial cells in B16F10 tumor vessels, further leading to
deficits in vascular basal lamina assembly.5 Those ex-
periments therefore did not allow us to analyze the re-
spective effects of pericyte/endothelial cell interaction
versus basal lamina deposition on tumor vessel develop-
ment and function. The observed collagen VI-dependent
deficits in basal lamina assembly nevertheless sug-
gested that use of the collagen VI-null mouse might pro-
vide a way of separating these two sets of effects. To
analyze the extent of pericyte coverage of endothelial
cells, sections of 7-day B16F10 tumors from wild-type
and collagen VI-null mice were analyzed by immuno-
staining for CD31 (vascular endothelial cells) and
PDGFR- (pericytes) (Figure 2, A–D). The abundance of
CD31-positive endothelial cells (Figure 2E) and the abun-
dance of PDGFR-–positive pericytes (Figure 2F) were
collagen
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levels of pericyte coverage of CD31-positive tumor ves-
sels were not significantly altered in collagen VI-null mice
(Figure 2G). Similar results were obtained with NG2 an-
tibody to label pericytes (data not shown), showing that
these results are independent of the choice of pericyte
marker. By counting numbers of CD31-positive blood
vessels, we also determined that vascular density was
not altered in tumors in collagen VI-null mice (Figure 2,
H–J). Thus, altered recruitment of pericytes and endothe-
lial cells, changes in the cellular composition of vessels,
Figure 1. Collagen VI ablation retards melanoma progression and reduces b
cells (104 cells) into the corpus callosum of wild-type and collagen VI-null
days, the average tumor size in collagen VI-null mice was twofold smaller t
B: At 7 days after injection, the average cross-sectional area of tumors in col
wild type. C–F: To evaluate basal lamina assembly associated with tumor blo
double-stained for collagen IV (red, C) and CD31 (green, D). CD31-positive tu
some segments of CD31-positive tumor vessels (F) in collagen VI-null mice w
Quantification of collagen IV pixels colocalized with CD31 pixels shows that vas
in the collagen VI-null mouse. *P 0.0059 versus wild type. H: Moreover, the a
VI-null mice. *P 0.0047 versus wild type. Immunolabeling for the ECM proteins
width in collagen VI-null mice. *P  0.0035 (I), *P  0.03 (J) versus wild type.changes in vessel density, and changes in pericyte cov-erage of endothelial cells are not likely to be responsible
for the deficits in basal lamina assembly observed in
7-day tumors in the collagen VI-null mouse.
Pericyte Maturation Is Retarded by Deficits in
Basal Lamina Assembly
Even though neither overall numbers of pericytes and endo-
thelial cells nor the spatial relationbetween these twocell types
in 7-day tumors is altered by collagen VI ablation, the details of
ina assembly in tumor vessels. A: After microinjection of B16F10 melanoma
mor sizes were measured at 7, 12, and 15 days after injection. At 12 and 15
-type mice. *P  0.0362, **P  0.0483 versus wild type at each time point.
-null mice was 80% of that measured in wild-type mice. *P  0.0222 versus
els, sections of 7-day tumors from wild-type and collagen VI-null mice were
sels were well covered by the collagen IV matrix in wild-type mice. In contrast,
rly enveloped by the collagen IV-positive basal lamina (E; arrows in F). G:
as not covered by collagen IV increase from 30% in the wild-type mouse to 46%
idth of the collagen IV-positive basal lamina was decreased by 45% in collagen
I (I) and laminin-111 (J) also showed similar reductions in vascular basal lamina
rs: 20 m (C–F). KO, knockout; WT, wild type.asal lam
mice, tu
han wild
lagen VI
od vess
mor ves
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previously found that pericyte maturation was retarded by re-
duced pericyte/endothelial cell interaction in NG2-null tumor
vessels, wewonderedwhether pericytematuration would also
be affected by deficits in basal lamina assembly. Double im-
munostaining for PDGFR- and the maturation marker -SMA
showed that 30% of tumor vessel pericytes in wild-type mice
were costained for both markers (Figure 3A). In contrast, the
percentage of PDGFR--positive pericytes expressing the
-SMAmaturation marker (Figure 3B) was reduced by 50% in
collagen VI-null mice (Figure 3C). Thus, even though pericyte
recruitment andcoverageof endothelial cells is not affectedby
collagen VI ablation, pericyte maturation is still retarded as a
Figure 2. Pericyte/endothelial cell dynamics and vessel density in collagen
of 7-day tumors from wild-type (A and B) and collagen VI-null (C and D) br
density of CD31 pixels is equal in tumors from wild-type mice and collagen
the extent of pericyte coverage of endothelial cells is not affected by collage
covered by green pixels in z-stacks of confocal images. CD31 labeling was us
VI-null (I) tumors, showing that vascular density is unchanged by collagen V
brain. Scale bars: 40 m (A–D); 180 m (H and I). KO, knockout; WT, wilresult of deficient basal lamina assembly.Sprouting of Endothelial Tip Cells Is Reduced by
Collagen VI Ablation
To determine whether deficits in basal lamina deposition
affect the development of endothelial cells as well as
pericytes, we examined VEGFR-3 as a marker expressed
in the filopodia of sprouting endothelial tip cells.16
VEGFR-3 was highly expressed in tumor blood vessels in
wild-type mice (Figure 3, D and E) but poorly expressed in
the vessels of normal brain (Figure 3E), reflecting the active
remodeling in progress in tumor vessels. At higher magni-
fication, a high ratio of VEGFR-3 expression to CD31 ex-
tumors. To assess pericyte investment of vascular endothelial cells, sections
re double-stained for CD31 (purple) and PDGFR- (green; B and D). E: The
mice. F: This is also true for the density of PDGFR- pixels. G: In addition,
ation, as determined by quantifying the percentage of purple pixels that are
antify the number of vessels per unit area in both wild-type (H) and collagen
on (J). Dashed line (I) indicates the border between the tumor and normalVI-null
ains we
VI-null
n VI abl
ed to qupression is apparent in sprouting endothelial tip cells in
ained fo
wild typ
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ber of these VEGFR-3-high, CD31-low sprouting endothelial
cells was conspicuously reduced in collagen VI-deficient
tumor vessels (Figure 3, G and H). Because VEGFR-3 is
also a marker for lymphatic endothelial cells, it was neces-
sary for us to show that the VEGFR-3-positive structures in
B16F10 tumors are not lymphatics. Although the brain has
no lymphatic drainage system, lymphatic-like tumor vessels
have been found in malignant human gliomas.19 We there-
Figure 3. Pericyte maturation and endothelial cell sprouting are reduced b
of 7-day tumors from wild-type (A) and collagen VI-null (B) mice were stained
and -SMA (red) to identify nascent and mature pericytes, respectively. C: T
by 50% in tumors from collagen VI-null mice (C). *P  0.0426 versus wild typ
and collagen VI-null (G) mice were double-stained for VEGFR-3 (red) a
immunoreactive, whereas vessels in normal brain were not positive for VEG
and normal brain. Typical sprouting endothelial cells are strongly positive fo
vessels in wild-type tumors (F, arrowheads), but they were significantly le
cells as a function of total vascular area showed that the number of sprouting
wild type. Tumor vessels positive for VEGFR-3 staining (J, red) were not cost
bars: 60 m (A, B, F, and G); 120 m (D, E, I, and J). KO, knockout; WT,fore used double labeling for VEGFR-3 and the lymphaticmarker LYVE-1 to show that VEGFR-3-positive vessels in the
B16F10 tumors are not lymphatics (Figure 3, I and J).
Endothelial Cell Apoptosis Is Increased in
Collagen VI-Deficient Tumor Vessels
In addition to reducing the sprouting of endothelial
cells, deficient basal lamina assembly in collagen VI-
null tumor vessels also causes increased endothelial
n VI ablation. To investigate pericyte maturation in tumor vessels, sections
31 to localize vessels (not shown) and also were stained for PDGFR- (green)
lation of mature pericytes (ie, positive for both pericyte markers) is reduced
aluate endothelial cell sprouting, 7-day tumor sections from wild-type (D–F)
1 (green). Most tumor vessels in wild-type mice were strongly VEGFR-3
, arrows). Dashed lines (D and E) indicate the border between the tumor
R-3 and only weakly positive for CD31. These cells were frequently seen in
dant in vessels from collagen VI-null tumors (G). H: Quantification of these
lial tip cells was reduced by 50% in collagen VI-null mice. *P 0.0088 versus
r LYVE-1 (I and J, green), showing that these are not lymphatic vessels. Scale
e.y collage
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hosts, activated caspase-3 labeling was scattered
throughout the tumor tissue, but it was rarely colocal-
ized with the endothelial cell marker CD31 (Figure 4, A
and B). In 7-day tumors from collagen VI-null mice, the
overall number of activated caspase-3-positive cells
was increased, and significantly, an increased portion
of this activated caspase-3 immunoreactivity was as-
sociated with CD31-positive tumor blood vessels (Fig-
ure 4, C and D). At higher magnification, we detected
elongated cells in collagen VI-null tumor vessels that
were stained for both activated caspase-3 and CD31,
indicative of apoptotic endothelial cells (Figure 4, E
Figure 4. Increased endothelial cell apoptosis in tumors from collagen VI-
scattered throughout 7-day tumors from wild-type mice (A and B), but they w
abundant in collagen VI-null mice (C and D) and were sometimes colabeled
VI-null tumors (E and F) contained significant numbers of elongated cells po
cell population increased 6.8-fold in tumors from collagen VI-null mice. *P
and I) did not express CD31 in wild-type mice (arrowheads). J: The abunda
versus wild type. Scale bars: 120 m (A–D); 13.3 m (E, F, H, and I). KO,and F). The population of apoptotic endothelial cells incollagen VI-deficient tumor vessels was increased al-
most sevenfold compared with wild-type tumor vessels
(Figure 4G). By comparison, the population of acti-
vated caspase-3-positive cells that were negative for
CD31 and had a round structure (ie, nonendothelial)
was increased by a factor of 2.4 in collagen VI-null
tumors (Figure 4, H–J).
Collagen VI-Deficient Vessels Exhibit Reduced
Patency and Increased Leakiness
Aberrant deposition of the vascular basal lamina in col-
e. Apoptotic cells identified by staining for activated caspase-3 (red) were
ly colabeled for CD31 (green). Activated caspase-3-positive cells were more
31 (arrow). Dashed lines (A–D) indicate the tumor/brain border. Collagen
both activated caspase-3 and CD31 (arrows). G: This apoptotic endothelial
9 versus wild type. Scattered round cells positive for activated caspase-3 (H
hese cells increased by a factor of 2.4 in collagen VI-null tumors. *P  0.0332
ut; WT, wild type.null mic
ere rare
for CD
sitive for
 0.046lagen VI-null mice, with resulting consequences for peri-
increas
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effects on the functionality of tumor blood vessels. To
address this possibility, we examined vessel patency (ie,
functional connection to the circulation) by perfusion with
FITC-LEA lectin and evaluated vessel leakiness by per-
fusion with FITC-dextran (250 kDa). In both types of tests,
vascular endothelia were identified by immunostaining
for CD31. In the case of vessel patency, almost all CD31-
positive tumor vessels in wild-type mice were stained by
FITC-LEA lectin, showing their connection to the circula-
tion (Figure 5A). However, some CD31-positive tumor
vessels in collagen VI-null mice were not labeled with
FITC-LEA lectin (Figure 5B). Thus, although almost all
tumor vessels are patent in wild-type mice, this value
falls to 75% in collagen VI-null mice (Figure 5C). Looking
at these data from another viewpoint, we determined that
the abundance of nonpatent vessels increases from 0.1
vessel per 10,000 m2 in wild-type tumors to 0.3 vessels
per 10,000 m2 in tumors from collagen VI-null mice
(Figure 5D).
In assays of vascular leakage, FITC-dextran was
largely retained within the boundaries of CD31-positive
vessels in wild-type tumor vessels (Figure 5E). In con-
Figure 5. Reduced vessel patency and increased vessel leakage in collagen
lectin injection (green; 3-minute circulation period) followed by immunohis
FITC-LEA lectin in tumors from wild-type mice (A). In collagen VI-null mic
suggestive of nonpatent vessels. C: Quantitative comparisons of FITC-LEA an
functionally connected to the circulation. *P  0.0066 versus wild type. D: W
nonpatent vessels is seen to increase threefold in collagen VI-null tumors
intravenous FITC-dextran injection (green, 10-minute circulation period) foll
boundaries. Most FITC-dextran in tumors from wild-type hosts was contai
amounts of FITC-dextran were found external to CD31-positive vessels in co
the percentage of total tumor area covered by extravascular green pixels, was
bars: 40 m (A and B); 180 m (E and F). KO, knockout; WT, wild type.trast, the amount of extravascular FITC-dextran wasmarkedly elevated in collagen VI-null mice (Figure 5F).
Quantification of FITC-dextran located external to CD31-
positive vessels showed a threefold increase in leakage
in the collagen VI-null mice (Figure 5G). Thus, aberrant
assembly and deposition of the vascular basal lamina in
collagen VI-null mice reduces the patency and increases
the leakiness of tumor blood vessels.
Vascular Deficits Lead to Increased Intratumoral
Hypoxia and Elevated Levels of HIF-1 in
Tumors in Collagen VI-Null Mice
To further compare tumor vessel functionality in wild-type
and collagen VI-null mice, we examined tumor hypoxia
via injection of a pimonidazole hypoxia probe. Immuno-
staining was then used to quantify the extent of intratu-
moral hypoxia. In contrast to low levels of hypoxia in
7-day tumors from wild-type mice (Figure 6A), pimonida-
zole-positive areas were significantly increased in tumors
from collagen VI-null mice (Figure 6B). Quantification of
pimonidazole-positive areas showed that intratumoral
hypoxia was increased 10-fold in collagen VI-null mice
tumors. A–D: Tumor vessel patency was assessed by intravenous FITC-LEA
stry for CD31 (red). Most CD31-positive tumor vessels were also stained by
CD31-positive tumor vessels were negative for lectin staining (B, arrows),
labeling indicate that 25% of tumor vessels in collagen VI-null mice are not
pressed as vessel number per 10,000 m2 of tumor area, the occurrence of
.0354 versus wild type. E–G: Leakiness of tumor vessels was assessed by
tissue fixation. Sections were stained for CD31 (red) to define blood vessel
in the boundaries of tumor blood vessels (E). By comparison, significant
I-null mice (F, arrows). The extent of FITC-dextran leakage, expressed as
ed threefold in collagen VI-null mice (G). *P 0.0395 versus wild type. ScaleVI-null
tochemi
e, some
d CD31
hen ex
. *P  0
owed by
ned with
llagen V(Figure 6C).
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hypoxia could lead to tumor cell necrosis.18 Even though
hypoxia is elevated in 7-day tumors in collagen VI-null
mice, we were not able to detect PI incorporation into
tumor cell nuclei at this time point. In 12-day tumors,
levels of hypoxia are increased in both wild-type and
collagen VI-null tumors (see Supplemental Figure S1,
A–D, at http://ajp.amjpathol.org), and we were able to
detect PI-labeled nuclei in both wild-type and collagen
VI-null tumors. The localization of PI-labeled nuclei within
hypoxic areas is shown (see Supplemental Figure S1,
E–G, at http://ajp.amjpathol.org). Nevertheless, the num-
bers of PI-labeled nuclei were very small in these tumors,
suggesting that necrosis is unlikely to be a big factor in
determining parameters of tumor behavior, including vas-
cularization, at least at the time points we examined.
Hypoxia is known to initiate a cascade of events that
affects subsequent vascular remodeling of hypoxic tis-
sues.20 Induction of HIF-1 is an early event in this sig-
naling cascade that leads among other things to up-
regulation of VEGF expression as a trigger for additional
vascularization.20 We therefore examined HIF-1 expres-
sion in tumors growing in wild-type and collagen VI-null
mice to confirm the correlation between hypoxia and
HIF-1 up-regulation. In nonhypoxic 7-day tumors grow-
Figure 6. Increased hypoxia and HIF-1 expression in tumors in collagen V
injection of a pimonidazole hypoxia probe (60 mg/kg, 1-hour circulation per
In contrast to very small pimonidazole-positive regions in wild-type tumors (
VI-null mice (B). Intratumoral hypoxia levels, defined as the percentage of t
VI-null mice (C). *P  0.0039 versus wild type. D–G: Levels of HIF-1 expr
pimonidazole (green) in sections of 7-day tumors. Neither hypoxia nor HIF-1
from collagen VI-null mice (E and F). Sites of HIF-1 up-regulation were usua
is increased fourfold in tumors from collagen VI-null mice (G). *P  0.0256
wild type.ing in wild-type mice, HIF-1 is difficult to detect at thelevel of immunofluorescence (Figure 6D). However, in
7-day tumors from collagen VI-null mice, HIF-1 immu-
noreactivity is readily detectable in cells that are usually
in close proximity to hypoxic areas (Figure 6, E and F).
Quantification of HIF-1 labeling shows a fourfold in-
crease in tumors from collagen VI-null mice (Figure 6G).
Altered Patterns of VEGF Expression in Tumors
in Collagen VI-Null Mice
Because HIF-1 is a main regulator of VEGF expression,
we also examined VEGF levels in tumors in wild-type and
collagen VI-null mice. Although 7-day tumors in collagen
VI-null mice are more hypoxic than wild-type tumors and
exhibit increased levels of HIF-1, VEGF expression was
not easily detectable by immunofluorescence in tumors
of either genotype. In both sets of tumors, very low levels
of VEGF could be seen in association with CD31-positive
blood vessels (Figure 7, A–D). By contrast, VEGF was
easily detectable in 12-day tumors in both genotypes
(Figure 7, E–H). VEGF localization occurred in two dis-
tinct patterns in 12-day tumors: closely associated with
CD31-positive blood vessels and more randomly distrib-
uted among tumor cells and stroma. In 12-day tumors in
ice. A–C: Hypoxia levels in 7-day tumors were determined after intravenous
mor sections were double-stained for pimonidazole (green) and CD31 (red).
s of intratumoral hypoxia were markedly increased in tumors from collagen
or area covered by pimonidazole pixels, were increased 10-fold in collagen
elative to hypoxia were evaluated by immunolabeling for HIF-1 (red) and
eadily apparent in tumors in wild-type mice (D) but was detected in tumors
in close proximity to areas of hypoxia (E and F, arrows). HIF-1 expression
wild type. Scale bars: 120 m (A and B); 40 m (D–F). KO, knockout; WT,I-null m
iod). Tu
A), area
otal tum
ession r
 was r
lly seenwild-type mice, vessel-associated VEGF was predomi-
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AJP March 2012, Vol. 180, No. 3Figure 7. Intratumoral VEGF expression and effects on tumor vessels. A–H: VEGF expression (red) in 7-day and 12-day tumors was evaluated by
immunofluorescence. At 7 days in both wild-type (A and B) and collagen VI-null (C and D) tumors, very low levels of VEGF (arrows) were detected in
association with CD31-positive vessels (green). At 12 days, VEGF levels were much increased in both wild-type (E and F) and collagen VI-null (G and H)
tumors. VEGF immunoreactivity in 12-day tumors was distributed in two distinct patterns: closely associated with CD31-positive blood vessels (E–H,
arrows) or more randomly dispersed among tumor cells or stroma (E–H, arrowheads). I and J: Quantification of these patterns of VEGF immunofluo-
rescence shows increased nonvascular VEGF (I) and decreased vascular VEGF (J) in collagen VI-null tumors relative to levels seen in wild-type tumors.
(I) *P  0.0005 versus 7-day wild type; †P  0.0025 versus 7-day collagen VI-null; ‡P  0.0424 versus 12-day wild type. (J) *P  0.018 versus 7-day wild
type; ‡P  0.0430 versus 12-day wild type. K–N: Immunolabeling for CD31 (green) also allowed assessment of vessel size in 12-day wild-type (K) and
collagen VI-null (L) tumors. Vessel size was quantified according to both the CD31-positive area (M) and diameter (N) of each vessel. By both
measurements, vessel size was decreased in collagen VI-null tumors. *P  0.0489 (M), *P  0.0394 (N) versus wild type. Scale bars: 120 m (A–H); 180
m (K and L). KO, knockout; WT, wild type.
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predominant in tumors in collagen VI-null mice (Figure 7,
G and H). Although quantification of VEGF pixels sug-
gested a slight increase in total VEGF expression in col-
lagen VI-deficient tumors (occupying 4.31% of tumor
area compared with 3.12% in wild-type tumors), this dif-
ference is not statistically significant. However, quantifi-
cation of VEGF expression patterns clearly shows in-
creased levels of nonvascular VEGF (Figure 7I) but
decreased levels of vascular VEGF (Figure 7J) in 12-day
collagen VI-null tumors, relative to levels seen in wild-type
tumors. Because of the ability of some VEGF isoforms to
bind to the ECM, we speculated that decreased vessel-
associated VEGF in the collagen VI-null tumors might be
due to the reduced vascular basal lamina assembly that
we observed in these tumors (Figure 1, C–J).
Because of the role of VEGF in stimulating angiogen-
esis, we also examined the vasculature in 12-day tumors
in wild-type and collagen VI-null mice (Figure 7, K and L).
Although we did not detect increased vascular density in
these tumors, we made the interesting observation that
average vessel size was significantly smaller in collagen
VI-null tumors as judged by both the CD31 pixel area
occupied by individual vessels (40.2% reduction; Figure
7M) and the vessel diameter (31% reduction; Figure 7N).
This reduction in vessel size may be linked to the dimin-
ished VEGF-binding capacity of the smaller basal lamina
formed in the absence of collagen VI.
Discussion
Because of the importance of both pericyte/endothelial
cell interactions and the vascular basal lamina in vessel
development and stabilization,1–4 we have been inter-
ested in trying to determine the relative importance of
these factors in vascular morphogenesis and mainte-
nance. This goal was not achievable in our previous
studies on the NG2-null mouse, in which deficits in basal
lamina assembly proved to be intimately linked to peri-
cyte/endothelial cell interaction.5 However, in the course
of that study, we noted that basal lamina assembly was
also diminished in the collagen VI-null mouse, possibly
because of loss of anchorage sites for other basement
membrane collagens such as collagens I and IV. This
suggested an alternative means of examining the impor-
tance of the vascular basement membrane in a model in
which the primary deficit is in basal lamina assembly
rather than in pericyte/endothelial cell interaction. Al-
though collagen VI has been observed to exert a variety
of effects on tumor growth as a component of various
elements of the tumor stroma,21,22 expression of this col-
lagen in the adult mouse brain is limited to the vascular
basement membrane. The ability of collagen VI to affect
the growth of intracranial B16F10 tumors in our study is
therefore largely restricted to its effects on the tumor
vasculature.
Accordingly, we have examined in detail the differ-
ences that exist between B16F10 tumor vessels in wild-
type and collagen VI-null mice. These differences are
summarized in Table 1. In addition to providing an envi-ronment for developing blood vessels, the tumors also
serve as an overall readout of vessel function, because
tumor growth is strictly limited by tumor vasculariza-
tion.12,13 Our results confirm that basal lamina assembly
is critical for vessel development and suggest that defi-
cits in this process probably account for most of the
decrease in vessel development and function that we
previously observed in the NG2-null mouse. Pericyte and
endothelial cell recruitment, pericyte coverage of endo-
thelial cells, and the abundance of vascular structures
are not affected by ablation of collagen VI in 7-day tu-
mors. However, even in the absence of changes at the
cellular level, the width of the basal lamina associated
with tumor blood vessels is reduced by 50% in collagen
VI-null mice, as judged by immunostaining for three dif-
ferent markers, collagen IV, collagen I, and laminin-111.
On the basis of known functions of collagen VI, it is likely
that this deficit stems from the role of collagen VI in
providing a link between cell surface receptors such as
NG2 and 1 integrins8,9,23,24 and other collagens such as
I and IV10,11,25 which are integral to basal lamina assem-
bly. The vascular phenotype of collagen VI-null mice is
actually mild compared with the phenotypes of mice with
knockouts of some other vascular basement membrane
components such as laminin-8, laminin-10, and collagen
IV. These null mice are either embryonic or early postna-
tal lethal,26–28 suggesting that collagen VI provides only
one of several possible mechanisms of anchorage for key
basal lamina components. For example, 1 integrins and
dystroglycans can serve as anchorage points for lamin-
Table 1. Changes in B16F10 Tumor Vessels in the Collagen
VI-Null Mouse Brain
Parameter
Days after injection
7 12
Basal lamina width 2-fold decrease ND
Pericyte density Unchanged ND
Pericyte/endothelial
cell coverage
Unchanged ND
Pericyte maturation 2-fold decrease ND
Endothelial cell density Unchanged ND
Vessel density Unchanged ND
Endothelial cell
sprouting
2-fold decrease ND
Endothelial cell
apoptosis
7-fold increase ND
Non-patent vessel
density
3-fold increase ND
Vessel leakiness 3-fold increase ND
Intratumoral hypoxia 10-fold increase ND
HIF-1 expression 4-fold increase ND
Non-vascular VEGF Unchanged 2-fold increase
Vessel-associated
VEGF
Unchanged 2-fold decrease
Vessel size Unchanged 1.5-fold
decrease
Tumor size 0.33-fold
decrease
2-fold decrease
With the use of B16F10 tumors from wild-type and collagen VI-null
mice, several parameters of blood vessel structure and function were
quantified as described in the Materials and Methods.
ND, not determined.ins and collagen IV, independent of collagen VI.29 The
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advantageous in terms of facilitating our vascular analy-
ses. A more devastating early phenotype would have
precluded such studies.
Despite the absence of large changes in the cellular
composition of tumor vessels in 7-day tumors in collagen
VI-null mice, detailed analyses found that deficiencies in
the collagen VI-null vascular basal lamina nevertheless
have negative effects on both pericyte and endothelial
cell development. Pericytes exhibit a delay in their ex-
pression of the maturation marker -SMA, indicating that
interaction with a robust basement membrane is neces-
sary for the ability of pericytes to acquire a mature phe-
notype. In the absence of interaction with a robust basal
lamina, endothelial cells exhibit reductions in the sprout-
ing activity that would be required for active expansion of
the tumor vasculature. In parallel, a large increase in
endothelial cell apoptosis is seen as a result of deficits in
the basal lamina. These observations are consistent with
previous data showing that endothelial cell proliferation,
sprouting, motility, and survival all depend on ECM at-
tachment. Activation of critical signaling pathways in en-
dothelial cells may be triggered by interaction of cell
surface integrins with ECM components or by stimulation
of cell surface receptors by matrix-bound growth factors
such as VEGF.30–35 These changes in pericyte and en-
dothelial cell development in 7-day tumors may have
effects on pericyte/endothelial cell interaction that are not
shown by our gross determinations of vascular cell num-
bers and vascular cell overlap at 7-day tumors. In turn,
undetected alterations in pericyte/endothelial cell inter-
action may further contribute to deficits in basal lamina
assembly, as we have seen with the NG2-null mouse.5
The observed changes in basal lamina assembly
translate into measurable deficits in 7-day tumor vessel
function in the collagen VI-null mouse. Vessels not func-
tionally connected to the circulation are increased three-
fold by collagen VI ablation, whereas vessel leakiness is
increased almost threefold and tumor hypoxia is in-
creased 10-fold. Increased intratumoral hypoxia in the
collagen VI-null mouse is accompanied by fourfold in-
creased expression of HIF-1, relative to that seen in
tumors in wild-type mice. Although HIF-1-dependent
effects on VEGF expression are not yet apparent in 7-day
tumors, by 12 days increased VEGF expression is evi-
dent in tumors in both wild-type and collagen VI-null
mice. We anticipated seeing increased vascular density
as a result of this increased VEGF expression, but this
was not the case. Instead, we observed interesting
changes in vessel size, with the diameter and area oc-
cupied by individual vessels in collagen VI-null tumors
decreasing compared with that of vessels in wild-type
tumors. This change occurred in parallel with changes in
VEGF expression patterns between wild-type and colla-
gen VI-null tumors. Although overall levels of total VEGF
expression are not significantly different in 12-day wild-
type and collagen VI-null tumors, VEGF associated with
tumor vessels is decreased twofold in collagen VI-null
tumors. The larger amount of vessel-associated VEGF in
wild-type tumors might be due to sequestration in the
vascular ECM, expression by endothelial cells, or bindingto endothelial cell VEGFR.15 In contrast, VEGF is largely
nonvascular in nature in collagen VI-null tumors and in-
stead is dispersed within the tumor and tumor stroma.
This nonvascular VEGF might represent isoforms ex-
pressed by tumor cells and/or tumor stromal cells in
response to intratumoral hypoxia. Because of the ob-
served deficits in vascular basal lamina assembly in tu-
mors in the collagen VI-null mouse, we speculate that the
reduced vascular localization of VEGF in these tumors
may be due to diminished sequestration of VEGF species
that normally bind to ECM components in wild-type tumor
vessels. The observed differences in vessel development
highlight the importance of ECM-bound VEGF in vessel
maturation.35
As a result of collagen VI-dependent changes in tumor
vessels, B16F10 tumors in collagen VI-null mice are only
half the volume of B16F10 tumors in wild-type mice. By
comparison, B16F10 tumor volumes were reduced three-
fold in NG2-null mice as a result of a 50% decrease in
vessel patency, a fourfold increase in vessel leakiness,
and a 20-fold increase in tumor hypoxia.5 Because these
two sets of experiments with collagen VI-null and NG2-
null mice were conducted independently, precise com-
parisons of the data are not really warranted. However,
the relative magnitudes of the various deficits in the two
models make it apparent that basal lamina deficiencies
probably account for most of the reduced vascular func-
tion and accompanying reduction of tumor growth that
occur in the NG2-null mouse as a result of impaired
pericyte/endothelial cell interaction.5 If the slightly larger
deficits in vessel function and tumor growth seen in the
NG2-null mouse are in fact real, these may be accounted
for by alterations in developmental changes that depend
heavily on pericyte/endothelial cell interaction, such as peri-
cyte quiescence, stabilization of endothelial cell junctions,
and other aspects of vessel homeostasis.1
Effective cross talk between pericytes and endothelial
cells is normally a requirement for the assembly of a
robust basal lamina, as emphasized by our results with
the NG2-null mouse.5 Although we have attempted to use
collagen VI ablation to disrupt basal lamina deposition in
a manner that is relatively independent of major changes
in pericyte/endothelial cell dynamics, in fact, we have
found that it is not really possible to completely dissociate
the respective contributions of pericytes, endothelial
cells, and the basal lamina to vessel development. Be-
cause of the interdependence of these three elements,
alterations in one compartment invariably have at least
some consequences in the other two. This is seen in our
current work in the delayed maturation of pericytes and in
the altered sprouting and survival of endothelial cells in the
absence of a normal basement membrane. Nevertheless,
our findings with the collagen VI-null mouse reinforce the
idea that basal lamina assembly is one of the key events in
the development and maturation of blood vessels.
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